Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives $13.63 Average PT from Brokerages

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been given a consensus recommendation of “Hold” by the seven ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $13.6250.

Several research firms have weighed in on VNDA. B. Riley Financial increased their price target on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Jefferies Financial Group raised their price objective on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research note on Wednesday, December 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, January 21st.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Wall Street bullishness around the upcoming PDUFA for Bysanti — analysts and models show large upside if the FDA approves the bipolar/schizophrenia treatment, which is keeping speculative demand alive. FDA Calendar: Vanda Stock (VNDA) Shows 126% Upside with Bysanti Decision on Deck
• Positive Sentiment: Brokerage consensus remains above neutral — some coverage still labels VNDA a buy or “moderate buy,” supporting a baseline of institutional interest ahead of the regulatory decision. Vanda Pharmaceuticals Inc. Given Consensus Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Trading was temporarily halted today for “VNDA” citing “News pending” — a pause that often precedes a material corporate or regulatory update and can amplify volatility when trading resumes.
• Neutral Sentiment: Widespread media attention: coverage and “buzz” ahead of the FDA verdict are driving elevated volume and short‑term momentum trading; that creates heightened risk/reward but not a clear directional signal until the decision. Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti
• Neutral Sentiment: HC Wainwright maintains a Buy rating and a $22 price target but issued large downward revisions to near‑term EPS estimates — a mixed signal that keeps upside narratives alive while flagging weaker near‑term profitability. HC Wainwright analyst notes on Vanda
• Negative Sentiment: Zacks Research downgraded VNDA from “strong‑buy” to “hold,” signaling reduced conviction among some sell‑side analysts and likely contributing to downward pressure. Zacks Research downgrade
• Negative Sentiment: HC Wainwright sharply cut FY2026 and quarterly EPS forecasts (materially worsening loss projections), increasing concern about near‑term cash flow and execution if Bysanti or other catalysts don’t offset the shortfall. HC Wainwright EPS revisions
• Negative Sentiment: Analyst commentary framing VNDA as a “high‑risk” trade ahead of PDUFA emphasizes downside risk if the FDA rejects or requests more data — this narrative pressures risk‑averse investors and may amplify selling. Vanda Pharma: High Risk, Heavily Discounted – Stock Ahead Of PDUFA This Week

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC raised its holdings in Vanda Pharmaceuticals by 611.3% during the second quarter. Stonepine Capital Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock valued at $1,180,000 after acquiring an additional 214,852 shares during the period. Squarepoint Ops LLC lifted its holdings in Vanda Pharmaceuticals by 96.5% in the 2nd quarter. Squarepoint Ops LLC now owns 153,345 shares of the biopharmaceutical company’s stock worth $724,000 after purchasing an additional 75,295 shares in the last quarter. R Squared Ltd purchased a new position in Vanda Pharmaceuticals in the 2nd quarter worth approximately $83,000. Inscription Capital LLC grew its holdings in Vanda Pharmaceuticals by 293.5% during the 4th quarter. Inscription Capital LLC now owns 63,878 shares of the biopharmaceutical company’s stock valued at $563,000 after buying an additional 47,646 shares in the last quarter. Finally, Martingale Asset Management L P raised its position in shares of Vanda Pharmaceuticals by 87.3% during the fourth quarter. Martingale Asset Management L P now owns 33,114 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 15,431 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Stock Down 5.6%

Vanda Pharmaceuticals stock opened at $5.76 on Thursday. Vanda Pharmaceuticals has a one year low of $3.81 and a one year high of $9.60. The stock has a fifty day moving average of $7.32 and a 200 day moving average of $5.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.38 and a current ratio of 2.39. The stock has a market cap of $340.47 million, a PE ratio of -1.54 and a beta of 0.62.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. The firm had revenue of $57.22 million for the quarter, compared to the consensus estimate of $59.28 million. As a group, sell-side analysts predict that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.